Levobupivacaina Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This prevents sodium influx needed for depolarisation, thereby inhibiting the initiation and propagation of nerve impulses and producing a reversible loss of sensation in the area where it is administered.

The dose of Levobupivacaina Kabi is determined by the prescribing clinician based on the type of procedure, patient characteristics, and route of administration. The prescriber selects the appropriate concentration, volume and injection technique to achieve the desired anesthetic effect.

Safety data for levobupivacaine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk, and under close medical supervision.

To order Levobupivacaina Kabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levobupivacaina Kabi contains levobupivacaine, the S‑enantiomer of bupivacaine, offering a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Clinicians often prefer levobupivacaine when a safer cardiac profile is desired, especially in high‑risk patients.

Levobupivacaina Kabi should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture and freezing. Inspect the vial for particulate matter before use and discard if the solution appears discoloured.

Levobupivacaina Kabi is administered by a qualified healthcare professional via epidural, intrathecal (spinal) or peripheral nerve block techniques, or as an infiltration injection. The solution is injected slowly under aseptic conditions, with dosage and volume tailored to the specific procedure.

Serious risks include cardiac arrhythmias, cardiac arrest, seizures, severe respiratory depression, prolonged motor block, allergic reactions and methemoglobinemia. Prompt recognition of toxicity signs and immediate supportive measures are essential to mitigate these potentially life‑threatening events.

Levobupivacaina Kabi should be avoided in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or in situations where a safer alternative anesthetic is preferred. Clinical judgment is required for each case.